Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis

source extracted confidence: high 2026-04-09
#humans #melatonin #heart-failure #quality-of-life #stroke-volume

Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis

Daliri et al., 2025 | Clin Cardiol | Meta Analysis

Citation

Daliri Abolfazl Sam, Goudarzi Nima, ... Kabir Kourosh. Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis. Clin Cardiol. 2025-Mar;48(3):e70107. doi:10.1002/clc.70107

Abstract

BACKGROUND: Heart failure as an advanced cardiac disease has a high incidence and prevalence in all societies nowadays. Many drugs and treatment methods have been discovered for improving heart failure patients' conditions till now in this way melatonin therapy is one of the less-known methods rarely used by clinicians. METHODS: To investigate the positive effect of melatonin on heart failure development, we conducted a systematic review and meta-analysis by searching valid databases with keywords based on the protocol. Based on the eligible criteria, four articles were selected for data synthesis and analysis after scanning the title and/or abstract and reading full-text. RESULTS: As a result of analysis, increasing ejection fraction (Mean difference: 2.39 [-1.82, 6.59] p = 0.27), NYHA (New York Heart Association Functional Class) (Odds ratio: 4.84 [1.00, 23.44] p = 0.05), and significant elevation of quality of life (Mean difference: -5.95 [-9.54, -2.35] p = 0.001) were observed. As the effect of melatonin, fatigue, and NT-Pro BNP were reduced but on the contrary sleep quality, appetite, and FMD (Flow-Mediated Dilation) significantly increased. CONCLUSION: Thus, melatonin, by increasing psychologic parameters and cardiac potency, could be advised as a novel drug for treatment and palliating heart failure patients.

Key Findings

As a result of analysis, increasing ejection fraction (Mean difference: 2.39 [-1.82, 6.59] p = 0.27), NYHA (New York Heart Association Functional Class) (Odds ratio: 4.84 [1.00, 23.44] p = 0.05), and significant elevation of quality of life (Mean difference: -5.95 [-9.54, -2.35] p = 0.001) were observed. As the effect of melatonin, fatigue, and NT-Pro BNP were reduced but on the contrary sleep quality, appetite, and FMD (Flow-Mediated Dilation) significantly increased.

Outcomes Measured

  • sleep quality

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition sleep

MeSH Terms

  • Humans
  • Melatonin
  • Heart Failure
  • Quality of Life
  • Stroke Volume
  • Ventricular Function, Left
  • Treatment Outcome

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Systematic Review, Meta-Analysis
  • Vertical: melatonin

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09